USC-UCLA Drug-Induced Liver Injury (DILI) Clinical Center.

USC-UCLA 药物性肝损伤 (DILI) 临床中心。

• 批准号: 8729479
• 负责人: ANDREW Abba STOLZ
• 金额: $ 33.49万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-30 至 2018-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8729479
• 关键词: Acute; Acute Liver Failure; African American; Alcoholic Liver Diseases; Area; Asia; Asians; Biological Markers; Body Weight decreased; California; Censuses; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Collection; County; County Hospitals; Data; Data Coordinating Center; Databases; Delaware; Development; Disease; Doctor of Philosophy; Enrollment; Etiology; Event; Funding; Future; Genes; Genetic; Genetic Polymorphism; Goals; Hepatology; Hispanics; Immune; Immune system; Immunologist; Incidence; Individual; Internet; Knowledge; Laboratories; Latin America; Los Angeles; Medical center; Medicine; Native Americans; Patient Recruitments; Patients; Pharmaceutical Preparations; Plant Preparations; Population; Population Heterogeneity; Proteomics; Reaction; Reporting; Research; Research Personnel; Resources; Rhode Island; Role; Scientific Advances and Accomplishments; Serum; Services; Site; Somatotype; Specimen; Surveys; Talents; Techniques; United States; United States National Institutes of Health; Viral; Vitamins; Work; acute drug induced liver toxicity; base; comparative; disorder control; drug mechanism; drug quality; experience; follow-up; genetic variant; human disease; insight; instrument; liver injury; medical schools; patient population; programs; public health relevance; research clinical testing; response; treatment trial; troglitazone; usnic acid

DESCRIPTION (provided by applicant): The USC-UCLA Drug-Induced Liver Injury Clinical Center (CC) application in response to RFA-DK-13-003 "Continuation and Expansion of the Drug Induced Liver Injury Network (DILIN)" hopes to continue to participate with the other CCs to advance the scientific knowledge and clinical evaluation of DILI. Our application will continue to combine the only two medical schools in Los Angeles County allowing us to continue to uniquely capture and enroll DILI cases into the Networks database supervised by the Data Coordinating Center (DCC). The 9.3 M residents of Los Angeles County (2011) are an unmatched resource composed of the most ethnically diverse population in the United States. Our application continues to utilize the expertise and talents from USC and UCLA medical centers. The enrollment of a large number of bona fide and ill patients with close follow up has demonstrated our CC's ability to capture DILIN cases in this diverse populations. The Specific Aims for the continuation of the USC-UCLA DILI CC are to: 1) Continue enrollment of high quality cases with collection of disease controls and acute cases for mechanistic studies; 2) Detailed analysis of cholestatic DILI due to HDS using genetic and serum analysis; 3) Immunological surveying of acute DILI cases compared with disease control to identify potential mechanism of liver injury; 4) Proteomic studies in acute cases of hepatocellular to identify mechanism of disease; and 5) Support of DILIN effort to develop assessment instruments and a treatment trial.

描述(申请人提供)：USC-UCLA药物性肝损伤临床中心(CC)申请是对RFA-DK-13-003《药物性肝损伤网络(DILIN)的延续和扩展》的响应，希望继续与其他CCS一起参与，促进DILI的科学知识和临床评估。我们的应用程序将继续合并洛杉矶县仅有的两所医学院，使我们能够继续以独特的方式捕获帝力病例，并将其录入由数据协调中心(DCC)监督的网络数据库。洛杉矶县的930万居民(2011年)是无与伦比的资源，由美国最具种族多样性的人口组成。我们的应用程序继续利用南加州大学和加州大学洛杉矶分校医疗中心的专业知识和人才。大量有密切随访的真实和患病患者的登记表明，我们的CC有能力在这些不同的人群中捕获DILIN病例。USC-UCLA DILI CC继续实施的具体目标是：1)继续招募高质量病例，收集疾病控制和急性病例用于机制研究；2)利用基因和血清分析详细分析HDS引起的胆汁淤积性DILI；3)对急性DILI病例和疾病对照病例进行免疫学调查，以确定肝损伤的潜在机制；4)对急性肝细胞疾病病例进行蛋白质组学研究，以确定疾病的发病机制；以及5)支持DILIN制定评估工具和进行治疗试验。